Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC.RVPH · Entity 8147 | Director | December 18, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REVIVA PHARMACEUTICALS HOLDINGS, INC.
Report date December 18, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2035-12-17 | Direct | 8,200 |
Reported balance
After 2025-12-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-18 · Grant · Acquired 8,200 · Balance 8,200 F1: This option award (the "Option") was made in accordance with the terms of the 2020 Equity Incentive Plan (the "2020 Plan") of Reviva Pharmaceuticals Holdings, Inc. (the "Company"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share ("Common Stock"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award (the "Option") was made in accordance with the terms of the 2020 Equity Incentive Plan (the "2020 Plan") of Reviva Pharmaceuticals Holdings, Inc. (the "Company"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share ("Common Stock"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2025 Filed Dec 19, 2025 16:17 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 8,200 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001437749-25-038444 · rdgdoc.xml · derivative · entry 1 Patel Purav · CIK 0001818246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,200 Underlying: Common Stock, par value $0.0001 per share · 8,200 shares Expires 2035-12-17 F1 · derivative.exercise_date: This option award (the "Option") was made in accordance with the terms of the 2020 Equity Incentive Plan (the "2020 Plan") of Reviva Pharmaceuticals Holdings, Inc. (the "Company"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share ("Common Stock"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 16:35 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 8,200 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001437749-24-037372 · rdgdoc.xml · derivative · entry 1 Patel Purav · CIK 0001818246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,200 Underlying: Common Stock, par value $0.0001 per share · 8,200 shares Expires 2034-12-09 F1 · derivative.exercise_date: This option award (the "Option") was made in accordance with the terms of the 2020 Equity Incentive Plan (the "2020 Plan") of Reviva Pharmaceuticals Holdings, Inc. (the "Company"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock ("Common Stock") subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 16:19 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 8,200 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001437749-23-031986 · rdgdoc.xml · derivative · entry 1 Patel Purav · CIK 0001818246 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,200 Underlying: Common Stock, par value $0.0001 per share · 8,200 shares Expires 2033-11-12 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 16:15 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | PurchaseCommon Stock, par value $0.0001 per share | 3,000 | $4.69 | $14,070.00 |
DisclosureSEC source: 0001437749-22-027849 · rdgdoc.xml · nonDerivative · entry 1 Patel Purav · CIK 0001818246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,547 Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 09:01 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 3,900 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001437749-22-027082 · rdgdoc.xml · derivative · entry 1 Patel Purav · CIK 0001818246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,900 Underlying: Common Stock, par value $0.0001 per share · 3,900 shares Expires 2032-11-09 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 16:32 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001437749-21-028321 · rdgdoc.xml · derivative · entry 1 Patel Purav · CIK 0001818246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock, par value $0.001 per share · 5,300 shares Expires 2031-12-07 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 16:31 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001437749-21-014950 · rdgdoc.xml · derivative · entry 1 Patel Purav · CIK 0001818246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock, par value $0.0001 per share · 4,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The Option will vest at the rate of thirty-three percent (33%) of the shares subject thereto upon the one year anniversary of December 14, 2020, and as to an additional thirty-three percent (33%) of the shares subject to the Option on each successive one year anniversary thereafter, provided that Awardee remains a director of the Company through each such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 17:09 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | GrantStock Option (right to buy) · Derivative | 15,227 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001437749-21-009049 · rdgdoc.xml · derivative · entry 1 Patel Purav · CIK 0001818246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,227 Underlying: Common Stock, par value $0.0001 per share · 15,227 shares Expires 2031-04-13 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The Option will vest at the rate of twenty-five percent (25%) of the shares subject thereto upon the one year anniversary of the date of grant, and as to an additional 2.0833% of the shares on the last day of each month thereafter. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.